Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers
低剂量分割放射治疗播散性腹腔内癌症的化学增强作用
基本信息
- 批准号:10327267
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAfghanistanApoptosisAttentionBiological AssayBiological MarkersC57BL/6 MouseCD8-Positive T-LymphocytesCancer PatientCarcinogensCarcinomatosisCellsChemotherapy-Oncologic ProcedureCisplatinCollaborationsCombined Modality TherapyDNA RepairDataDiseaseDoseDown-RegulationEnzymesExposure toFluorescenceFluorouracilFractionated radiotherapyFukushimaGastric AdenocarcinomaGenesHumanHydrogen PeroxideHypoxiaImmuneImmune responseImmunocompetentImmunologistInfiltrationInjectionsIntra-abdominalIonizing radiationIraqJapanKnowledgeLow Dose RadiationMalignant neoplasm of abdomenMalignant neoplasm of gastrointestinal tractMeasuresMediatingMethodsModelingMolecularMonitorMorphologyMusNormal tissue morphologyNuclear AccidentsNude MiceOxidasesPathologistPatientsPerfusionPeritonealPost-Transcriptional RegulationProductionProliferatingProteinsRadiation Dose UnitRadiation ToleranceRadiation therapyReactive Oxygen SpeciesRectal CancerRecurrenceRegimenRegulatory T-LymphocyteResearchRoleSerumStomachStomach CarcinomaTestingTherapeuticTimeTissuesToxic effectTranscriptional RegulationUp-RegulationWorkXenograft ModelXenograft procedureburn pitcancer therapychemotherapyclinical applicationdensitydocetaxelfractionated radiationgastric cancer cellin vivoinsightmacrophagemalignant stomach neoplasmmouse modelnoveloptical imageroxidative damagepatient stratificationpreclinical studyprogramsradiation resistanceresponsestem cellstreatment responsetumortumor microenvironmenttumor progression
项目摘要
Whole abdominal radiotherapy (WART) is a primary method for managing gastrointestinal cancers that
have disseminated into intra-abdominal tissues. While effective, this approach is limited since combination of
WART with full-dose chemotherapy regimens increase toxicity to normal tissue. Recent studies have
demonstrated a survival advantage in a novel treatment paradigm that allows for the safe use of full-dose
systemic chemotherapy in combination with Low Dose Fractionated Radiotherapy (LDFRT). Traditionally,
radiotherapy used doses greater than 1.20 Gy because it was thought that lower radiation doses would be
ineffective for tumor therapy. We now know that LDFRT can produce hyper-radiosensitivity (HRS), a
phenomenon where cells undergo apoptosis at radiation doses as low as 0.15 Gy, in a number of proliferating
cells. Our objectives are to develop pre-clinical studies to investigate the therapeutic potential of
chemopotentiation by LDFRT in disseminated intra-abdominal cancer. Our data indicate that three
consecutive daily fractions of 0.15 Gy produced HRS in gastric cancer cells and potentiated a modified
regimen of Docetaxel, Cisplatin, and 5’-fluorouracil (mDCF). Colony survival assays indicated that 0.15 Gy was
sufficient to kill 90% of the cells when LDFRT was combined with mDCF whereas an almost ten times higher
dose (1.35 Gy) was needed to achieve the same rate when using conventional radiotherapy alone. RT2 PCR
Profiler Array analysis of more than 300 genes indicated that Dual Oxidase 2 (DUOX2), an enzyme functioning
in the production of hydrogen peroxide, was by far the most upregulated gene in response to this combined
regimen while genes involved in DNA repair were apparently not involved. Moreover, down regulation of
DUOX2 increased radioresistance at every radiation doses tested. In addition, our data indicate that Reactive
Oxygen Species increase up to 3.5 fold in cells exposed to LDFRT and mDCF. Furthermore, inhibition of
NAD(P)H oxidase abrogated the killing efficiency of this combined regimen. These findings are particularly
important given that DUOX2 is only expressed in about 50% of gastric carcinoma (preliminary data). DUOX2
could thus be used as a biomarker to potentially stratify gastric cancer patients with advanced and metastatic
intra-abdominal cancers for clinical applications of chemopotentiation by LDFRT. Our working hypothesis is
that Chemopotentiation by LDFRT is mediated by DUOX2 in gastric cancers. In order to test this hypothesis
three Specific aims have been developed. Aim 1. Determine the role of DUOX2 on human gastric cancer cells
progression in response to chemopotentiation by LDFRT in vivo. We will use human gastric cancer cells
expressing endogenous and reduced levels of DUOX2 and a fluorescence marker in mouse xenograft models.
Cancer progression will be monitored with a Xenogen IVIS optical imager following treatments. In addition, we
will determine whether activation of DUOX2 can be used as a biomarker for the combined regimen by
measuring Reactive Oxygen Species (ROS) and oxidative damage to proteins by measuring protein carbonyl
levels in mice serum. Aim 2: Delineate the molecular mechanisms leading to DUOX2 upregulation in response
to chemopotentiation by LDFRT. Emphasis will be on DUOX2 transcriptional and post-transcriptional
regulation. In Aim 3, we will evaluate the effect of DUOX2 on the immune response and the tumor
microenvironment. This will be performed in a syngeneic mouse model where DUOX2 effect on vasculature,
hypoxia, immune cells infiltration, and stem cells will be monitored. The unique aspect of this proposal is the
identification of DUOX2 as a major contributor to chemopotentiatoin by LDFRT and the possibility to revisit
WART with radiation doses ten times lower than the conventional dose in an attempt to decrease intra-
abdominal recurrence of the disease. In addition to providing insight into the molecular mechanisms
underlying therapeutic responses to low dose radiation, these studies could also be used to identify markers
for exposure to ionizing radiation.
全腹放射治疗(WART)是治疗胃肠道癌症的主要方法,
已经扩散到腹腔内组织虽然有效,但这种方法是有限的,因为
WART与全剂量化疗方案增加了对正常组织的毒性。最近的研究
证明了在一种新的治疗模式中的生存优势,这种治疗模式允许安全使用全剂量
全身化疗联合低剂量分次放疗(LDFRT)。传统上,
放射治疗使用大于1.20戈伊的剂量,因为人们认为较低的辐射剂量
对肿瘤治疗无效。我们现在知道LDFRT可以产生超放射敏感性(HRS),
在许多增殖的细胞中,细胞在低至0.15戈伊的辐射剂量下经历凋亡的现象。
细胞我们的目标是开展临床前研究,以调查
LDFRT在播散性腹腔内癌中的化学增强作用。我们的数据显示,
连续每日剂量为0.15戈伊可在胃癌细胞中产生HRS,并增强了改良的
多西他赛、顺铂和5 '-氟尿嘧啶(mDCF)方案。集落存活测定表明,0.15戈伊是
当LDFRT与mDCF组合时,足以杀死90%的细胞,而当LDFRT与mDCF组合时,几乎高十倍
当单独使用常规放射治疗时,需要1.35戈伊的剂量来达到相同的率。RT2 PCR
对300多个基因的Profiler阵列分析表明,双氧化酶2(DUOX 2),一种功能酶,
在过氧化氢的产生中,是迄今为止对这种组合的反应中上调最多的基因。
方案,而参与DNA修复的基因显然不参与。此外,下调
DUOX 2在每个辐射剂量下都增加了辐射抗性。此外,我们的数据表明,
在暴露于LDFRT和mDCF的细胞中,氧物质增加高达3.5倍。此外,抑制
NAD(P)H氧化酶消除了这种联合方案的杀伤效率。这些发现特别
重要的是,DUOX 2仅在约50%的胃癌中表达(初步数据)。DUOX2
因此,可以用作生物标志物,以潜在地对晚期和转移性胃癌患者进行分层。
腹腔内癌症的LDFRT化学增强的临床应用。我们的假设是
在胃癌中LDFRT的化学增强作用由DUOX 2介导。为了验证这个假设
制定了三个具体目标。目标1.确定DUOX 2对人胃癌细胞的作用
LDFRT在体内对化学增强作用的反应进展。我们将使用人类胃癌细胞
在小鼠异种移植模型中表达内源性和降低水平的DU 0X 2和荧光标记物。
治疗后将使用Xenogen IVIS光学成像仪监测癌症进展。另外我们
将确定DUOX 2的激活是否可用作联合方案的生物标志物,
通过测量蛋白质羰基来测量活性氧(ROS)和对蛋白质的氧化损伤
小鼠血清中的水平。目的2:阐明导致DUOX 2上调的分子机制
LDFRT的化学增强作用。重点将放在DUOX 2转录和转录后
调控在目标3中,我们将评估DUOX 2对免疫应答和肿瘤的影响。
微环境。这将在同基因小鼠模型中进行,其中DUOX 2对血管系统有影响,
将监测缺氧、免疫细胞浸润和干细胞。该提案的独特之处在于,
通过LDFRT鉴定DUOX 2为化学增强作用的主要贡献者,并可能重新评估
WART的辐射剂量比传统剂量低十倍,试图减少内部-
腹部复发的疾病。除了提供对分子机制的深入了解外,
低剂量辐射的潜在治疗反应,这些研究也可用于识别标记物
暴露在电离辐射下
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
France Carrier其他文献
France Carrier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('France Carrier', 18)}}的其他基金
Preclinical Evaluation of Radioprotectin-1 for Mitigation of GI-ARS
Radioprotectin-1 缓解 GI-ARS 的临床前评估
- 批准号:
10770849 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
相互协作辐射对策 (INTERACT) 联盟,促进减轻/治疗急性和迟发性辐射综合症的医疗对策高级发展
- 批准号:
10401455 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
相互协作辐射对策 (INTERACT) 联盟,促进减轻/治疗急性和迟发性辐射综合症的医疗对策高级发展
- 批准号:
10665553 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers
低剂量分割放射治疗播散性腹腔内癌症的化学增强作用
- 批准号:
9349730 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8866371 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
9089875 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8560772 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8688187 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
Drought and Climate Resilience of Smallholders in Afghanistan: Needs and Preferences Analysis
阿富汗小农的干旱和气候抵御能力:需求和偏好分析
- 批准号:
24K16366 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
'Diaspora States' in Somalia and Afghanistan: New Perspectives on Post-War Politics, Dual Citizenship and International Statebuilding
索马里和阿富汗的“侨民国家”:战后政治、双重国籍和国际国家建设的新视角
- 批准号:
EP/X022048/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship
Improving learning outcomes in Afghanistan and Pakistan in the midst of COVID-19 through Community based system dynamics and project-based learning
通过基于社区的系统动态和基于项目的学习,在 COVID-19 期间改善阿富汗和巴基斯坦的学习成果
- 批准号:
ES/X014088/1 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Research Grant
On Politics and Justice: British Military Justice following War Crimes Allegations in Iraq and Afghanistan, 2001-present
论政治与司法:2001 年至今,伊拉克和阿富汗战争罪指控后的英国军事司法
- 批准号:
2745904 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship
U.S and Afghanistan - why the nation-building project failed?
美国和阿富汗——国家建设项目为何失败?
- 批准号:
22K01385 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Market Economy and Conflict; Disjuncture between the Politics and Economics of Statebuilding in Afghanistan during 2001-2021
市场经济与冲突;
- 批准号:
ES/X006832/1 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Fellowship
Analysis of the structure of conflict between ethnicities in the transformation of national integration policy in Afghanistan
阿富汗民族融合政策转型中的族群冲突结构分析
- 批准号:
19K20529 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
神经类固醇干预伊拉克/阿富汗时期退伍军人的创伤后应激障碍
- 批准号:
10417141 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
神经类固醇干预伊拉克/阿富汗时期退伍军人的创伤后应激障碍
- 批准号:
10589071 - 财政年份:2019
- 资助金额:
-- - 项目类别:
A pilot assessment of miltefosine's efficacy and tolerability for treating cutaneous Leishmania tropica in Afghanistan
在阿富汗对米替福辛治疗皮肤热带利什曼原虫的疗效和耐受性进行初步评估
- 批准号:
MR/R018391/1 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Research Grant